Tenax Therapeutics (TENX) Stock Price, Quote & News

Company Profile

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was for...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 855 2100

Website: www.tenaxthera.com

Address:

101 Glen Lennox Drive, Suite 300, Chapel Hill, United States

biospeculator Apr. 29 at 9:42 PM

$TENX In Nov. 2025 only 6 months ago I bought shares at $6+. At the time the shares available were 7M for a market cap of $43M. Six months later without any news releases we find 25M shares and a market cap of $325M. In addition, the institutional ownership went from 120% to today's number per NASDAQ of 31% due to this unprecedented dilution. My target at the time was 500M if the phase III is successful. It is with pleasure I sold this and now will remove it from my screen. This is biotech and Wall Street imo at its worst. Management should imo be barred from running a public company.

1 · Reply

laaarsas Apr. 28 at 7:03 PM

$TENX hi donkeys. whats up here today?

0 · Reply

Jonita Apr. 28 at 3:08 PM

$TENX in in in

0 · Reply

kshonstocks Apr. 27 at 5:23 PM

$TENX terrific volume bar today

0 · Reply

cloudhedge Apr. 27 at 3:21 PM

🚨 $TENX Update 🚨 Caught a solid entry at $14.8, and now it's pulling back! 🔥 This could be the perfect setup for a swing trade heading into their Q3 data release. 🚀 With solid institutional backing and key data on the horizon, the potential for a run to $20+ is looking strong. 📊 The daily chart is looking clean — RSI is holding steady, and volume is there. If we get a nice breakout, $20 is in sight before the data drop! 🚀💥 What do you guys think? Anyone else eyeing this move? Drop your thoughts below! ⬇️

0 · Reply

OfficialStocktwitsUser Apr. 27 at 1:32 PM

$TENX RSI: 45.98, MACD: -0.0002 Vol: 0.67, MA20: 14.51, MA50: 13.67 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

squiggleburp Apr. 25 at 4:01 PM

$TENX Still looking for an entry. GTC set!

0 · Reply

Beppoker Apr. 23 at 12:02 PM

$TENX dentro

1 · Reply

DARKP00L Apr. 22 at 11:12 AM

$TENX 07:07 on Apr. 22 2026 Tenax Therapeutics Appoints Thomas R. Staab II CFO Effective May 11, Replacing Interim CFO McGauley #tradeideas

0 · Reply

Publicola29 Apr. 21 at 2:19 PM

$TENX where this go if it hits?

1 · Reply

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Mar 10, 2026, 2:20 PM EDT - 7 weeks ago

Tenax Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 7:00 AM EDT - 7 weeks ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 3, 2026, 7:00 AM EST - 2 months ago

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Feb 11, 2026, 12:30 PM EST - 2 months ago

Tenax Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 3 months ago

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Dec 17, 2025, 9:16 AM EST - 4 months ago

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Dec 4, 2025, 11:30 AM EST - 5 months ago

Tenax Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 4:15 PM EST - 5 months ago

Tenax Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 7:00 AM EST - 5 months ago

Tenax Therapeutics to Participate in Upcoming Investor Conferences

Nov 13, 2025, 4:30 PM EST - 5 months ago

Tenax Therapeutics Transcript: KOL Event

Nov 12, 2025, 4:05 PM EST - 6 months ago

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 4:00 PM EST - 6 months ago

Tenax Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:00 AM EST - 6 months ago

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Nov 3, 2025, 7:00 AM EST - 6 months ago

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Sep 16, 2025, 7:00 AM EDT - 8 months ago

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

Sep 4, 2025, 10:20 AM EDT - 8 months ago

Tenax Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 7:00 AM EDT - 8 months ago

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 1 year ago

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 7, 2025, 3:45 PM EDT - 1 year ago

Tenax Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 1 year ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 10, 2025, 3:40 PM EDT - 1 year ago

Tenax Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 8:47 AM EST - 1 year ago

Tenax Therapeutics Announces $25 Million Private Placement

Mar 5, 2025, 8:42 AM EST - 1 year ago

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Mar 3, 2025, 8:00 AM EST - 1 year ago

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Feb 5, 2025, 3:00 PM EST - 1 year ago

Tenax Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 31, 2025, 9:00 AM EST - 1 year ago

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Nov 13, 2024, 7:00 AM EST - 1 year ago

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Aug 6, 2024, 7:13 AM EDT - 1 year ago

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

May 14, 2024, 8:00 AM EDT - 2 years ago

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Apr 9, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Mar 28, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Feb 29, 2024, 9:00 AM EST - 2 years ago

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Feb 20, 2024, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Feb 8, 2024, 8:16 AM EST - 2 years ago

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Feb 7, 2024, 8:01 PM EST - 2 years ago

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 6, 2024, 10:01 AM EST - 2 years ago

Biotech stock Tenax Therapeutics more than doubled on Tuesday

Feb 6, 2024, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Dec 29, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Reverse Stock Split

Nov 17, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A.

Nov 13, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

Jul 19, 2023, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

May 31, 2023, 8:54 AM EDT - 3 years ago

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Apr 12, 2023, 8:45 AM EDT - 3 years ago

Tenax Therapeutics Provides 2023 Business Update

Mar 22, 2023, 8:45 AM EDT - 3 years ago

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 3, 2023, 8:19 AM EST - 3 years ago

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

Feb 1, 2023, 4:31 PM EST - 3 years ago

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Oct 10, 2022, 8:30 AM EDT - 3 years ago

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Sep 15, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

May 23, 2022, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 18, 2022, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

Mar 31, 2022, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Mar 30, 2022, 5:00 PM EDT - 4 years ago

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

Jan 31, 2022, 4:10 PM EST - 4 years ago

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

Jan 12, 2022, 8:30 AM EST - 4 years ago

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

biospeculator Apr. 29 at 9:42 PM

1 · Reply

laaarsas Apr. 28 at 7:03 PM

$TENX hi donkeys. whats up here today?

0 · Reply

Jonita Apr. 28 at 3:08 PM

$TENX in in in

0 · Reply

kshonstocks Apr. 27 at 5:23 PM

$TENX terrific volume bar today

0 · Reply

cloudhedge Apr. 27 at 3:21 PM

0 · Reply

OfficialStocktwitsUser Apr. 27 at 1:32 PM

0 · Reply

squiggleburp Apr. 25 at 4:01 PM

$TENX Still looking for an entry. GTC set!

0 · Reply

Beppoker Apr. 23 at 12:02 PM

$TENX dentro

1 · Reply

DARKP00L Apr. 22 at 11:12 AM

$TENX 07:07 on Apr. 22 2026 Tenax Therapeutics Appoints Thomas R. Staab II CFO Effective May 11, Replacing Interim CFO McGauley #tradeideas

0 · Reply

Publicola29 Apr. 21 at 2:19 PM

$TENX where this go if it hits?

1 · Reply

Reanimated666 Apr. 21 at 12:32 PM

$TENX The performance of this team should be watched by all who own this stock. If you need to ask why GTFO now

0 · Reply

squiggleburp Apr. 18 at 5:59 PM

$TENX Another one I have been tracking. Looking for a dip to $12 ish. Another ticker that has been in a range offering 20- percent swings. No position yet. Waiting, watching, charting and BURPING! BURP!

0 · Reply

Narutoosaka Apr. 17 at 1:58 PM

$TENX buying every Friday

0 · Reply

Kewlpapa Apr. 16 at 7:47 PM

$TENX got a starter here

0 · Reply

BiotechGoldenEra Apr. 16 at 2:46 AM

$TENX let’s go

0 · Reply

vjtweet Apr. 14 at 9:42 PM

$TENX on watch list.. yet to make a move.

0 · Reply

Quantumup Apr. 13 at 8:25 PM

Stifel🏁 $TECX and said: We're initiating coverage of TECX with a Buy and $75 TP. $TENX $MRK IBIO $AZN Here's what else Stifel had to say: https://x.com/Quantumup1/status/2043785964942729374?s=20

0 · Reply

LongBallBarn Apr. 10 at 9:24 AM

$TENX $SYRA $SYPR $VTVT

0 · Reply

Narutoosaka Apr. 9 at 9:45 PM

$TENX https://www.youtube.com/live/NXEmFGEurkQ?si=lTruY-KyvpqwAyv9

1 · Reply

Narutoosaka Apr. 7 at 3:46 PM

$TENX i am a buyer until hit 20s

0 · Reply

LongBallBarn Apr. 6 at 3:54 PM

$TENX New 52 wk high coming soon

0 · Reply

Narutoosaka Apr. 6 at 3:22 PM

$TENX 🤣🤣🤣

0 · Reply

Market Cap	251.09M
Revenue (ttm)	0.00
Net Income (ttm)	-52.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	548,100
Avg Vol	470,292
Day's Range	N/A - N/A
Shares Out	17.20M
Stochastic %K	3%
Beta	1.19
Analysts	Strong Sell
Price Target	$28.67